Sanofi SA · ISIN: FR0000120578

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 13.01.2025 | 06:00
13 January 2025 06:00AM
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma...
© Globe Newswire
09 January 2025 06:00AM
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma...
© Globe Newswire
23 December 2024 06:00AM
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines...
© Globe Newswire
19 December 2024 05:00PM
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of Directors...
© Globe Newswire
13 December 2024 06:00AM
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis...
© Globe Newswire
11 December 2024 06:00AM
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US...
© Globe Newswire
09 December 2024 07:06PM
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients...
© Globe Newswire
07 December 2024 04:30PM
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP...
© Globe Newswire
06 December 2024 06:30AM
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Availability of the revised financial statements for Sanofi excluding Opella...
© Globe Newswire
20 November 2024 01:11PM
Sanofi: Information concerning the total number of voting rights and shares - October 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
© Globe Newswire
15 November 2024 06:00AM
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria...
© Globe Newswire
06 November 2024 06:00AM
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis...
© Globe Newswire
15 October 2024 08:05PM
Sanofi: Information concerning the total number of voting rights and shares - September 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
© Globe Newswire
11 October 2024 06:30AM
Press Release: Sanofi in discussions to sell a controlling stake in Opella
Sanofi in discussions to sell a controlling stake in Opella...
© Globe Newswire
09 October 2024 05:00AM
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
 ...
© Globe Newswire
27 September 2024 01:35PM
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
 ...
© Globe Newswire
27 September 2024 11:00AM
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for patients with COPD...
© Globe Newswire
26 September 2024 05:30AM
Press Release: Availability of the Q3 2024 Aide mémoire
Availability of the Q3 2024 Aide mémoire...
© Globe Newswire
20 September 2024 10:36PM
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant        ...
© Globe Newswire
20 September 2024 11:45AM
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old...
© Globe Newswire
20 September 2024 09:30AM
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study...
© Globe Newswire
16 September 2024 04:44PM
Sanofi: Information concerning the total number of voting rights and shares - August 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
© Globe Newswire
12 September 2024 05:00AM
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers...
© Globe Newswire
11 September 2024 05:05AM
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
 ...
© Globe Newswire
11 September 2024 05:00AM
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
 ...
© Globe Newswire
02 September 2024 05:00AM
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
 ...
© Globe Newswire
09 August 2024 07:11PM
Sanofi: Information concerning the total number of voting rights and shares - July 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
© Globe Newswire
08 August 2024 05:00AM
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant...
© Globe Newswire
25 July 2024 02:57PM
Press Release: Online availability of Sanofi’s half-year financial report for 2024
Online availability of Sanofi’s half-year financial report for 2024...
© Globe Newswire
22 July 2024 08:05PM
Sanofi: Information concerning the total number of voting rights and shares – June 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
© Globe Newswire
17 July 2024 09:27PM
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
  ...
© Globe Newswire
03 July 2024 05:00AM
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD...
© Globe Newswire
26 June 2024 09:30PM
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM...
© Globe Newswire
25 June 2024 05:32PM
Press Release: Availability of the Q2 2024 Aide-mémoire
Availability of the Q2 2024 Aide-mémoire...
© Globe Newswire
21 June 2024 07:30AM
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee...
© Globe Newswire
21 June 2024 05:00AM
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran...
© Globe Newswire
12 June 2024 06:19PM
Sanofi: Information concerning the total number of voting rights and shares – May 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
© Globe Newswire
03 June 2024 08:15PM
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3...
© Globe Newswire
31 May 2024 10:00AM
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan...
© Globe Newswire
31 May 2024 05:05AM
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
Dupixent recommended for EU approval by the CHMP to treat patients with COPD...
© Globe Newswire
31 May 2024 05:00AM
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
 ...
© Globe Newswire
30 May 2024 01:01PM
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc....
© Globe Newswire
27 May 2024 05:00AM
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
 ...
© Globe Newswire
21 May 2024 05:30AM
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration...
© Globe Newswire
20 May 2024 08:54PM
Sanofi: Information concerning the total number of voting rights and shares - April 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
© Globe Newswire
20 May 2024 06:15PM
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
 ...
© Globe Newswire
13 May 2024 05:00AM
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
 ...
© Globe Newswire
10 May 2024 06:00AM
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
  Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines...
© Globe Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.